Daniel O'day on acquisitions
From $GILD Gilead Sciences Q1 2026 Earnings Conference Call · · EARNMOAR
“Our acquisition of Arcelix, which closed on April 28th, reflects our conviction in the potential of Anitacel as a differentiated option for patients with multiple myeloma. Given the significant opportunity in fourth line as well as earlier lines of therapy, we believe Anitacel could become a foundational therapy for multiple myeloma, driving growth in our cell therapy business in 2027 and beyond.”
On , Daniel O'day, Chairman & Chief Executive Officer at Gilead Sciences, Inc., spoke about acquisitions during $GILD Gilead Sciences Q1 2026 Earnings Conference Call on EARNMOAR.
About Daniel O'day
Daniel O'Day, chairman and chief executive officer of Gilead Sciences, has been discussing the company's financial performance and pipeline developments across multiple earnings calls and public appearances. In the third quarter of 2025, he stated that Gilead was increasing its full-year HIV revenue growth expectations to approximately 5% despite a $900 million headwind from the Medicare Part D redesign, and noted that the company has no major patent losses until 2036. He also said that more than 80% of Gilead's intellectual property is recognized in the United States and that 90% of its taxes are paid there. In the first quarter of 2026, O'Day described the company's portfolio as the strongest in its history, citing recent acquisitions of Arcellx, Oral Medicines, and Tubulis, and said Gilead expected up to four potential product launches and five phase three readouts by the end of the year. At the Semafor World Economy event in April 2026, O'Day discussed the company's HIV prevention drug lenacapavir, which he described as a twice-yearly injection developed over 17 years. He said Gilead is producing the drug at no profit and working with the Global Fund and PEPFAR to distribute it to low- and low-middle-income countries, and that an interim commitment had been expanded from reaching two million people to three million people over the next three years. He also stated that Gilead voluntarily licensed the medicine to generic manufacturers with no royalties, calling it "a part of our responsibility to society." On drug pricing in the United States, O'Day said that "50 cents on every dollar goes to people that never discover or develop the medicines" and that the company supports reforms that reduce out-of-pocket costs for patients while preserving innovation.